SynGenSys Introduces Expanded CHO.SET Synthetic Promoter Library for Enhanced Biomanufacturing

 CHO.SET 2.0 library of synthetic promoters offers tunable expression of transgenes whilst increasing CHO cell productivity. CHO.SET promoters allow increasing protein titres, lower expenses and limited advancement timelines.

SynGenSys, a biotechnology company designing synthetic gene supporter technology to address significant bottlenecks in biopharma production and improve cell and gene therapy development, announced the introduction of CHO.SET 2.0. The increased library of novel and patentable synthetic organizers is designed to enhance protein production in CHO (Chinese Hamster Ovary) cells.

The CHO.SET Library was first introduced in 2024 and has since increased and been optimized, reflecting SynGenSys’ sustained commitment to tackle important biomanufacturing bottlenecks. Existing market vectors rely heavily on natural promoters like CMV and SV40E, which limit transcriptional activity and are insufficient for generating the increasing productivities needed for modern commercial biotechnology requests. Advanced de novo design uses the organization’s proprietary transcriptional analysis and sequence engineering platform, CHO.SET synthetic promoters integrate advanced computational design with empirical validation to supply an enormously diverse promoter library applicable in a wide range of CHO expression technology and biomanufacturing needs.

Advanced supporting information demonstrates that CHO.SET promoters outperform standard industry promoters, delivering improved transcriptional activity and enhanced protein manufacturing metrics. Selected vectors present to achieve over 4x higher antibody output, with titres exceeding 2 g/L in a simple fed-batch flask model. The CHO.SET synthetic promoter pools contain an increasing proportion of high-expressing cells, increasing the likelihood of dividing top-performing clones. CHO.SET supports more efficient and efficient cell line development workflows, achieving high titers without the need for MSX, reducing process complexity and enabling faster recovery timelines and route to materials for toxicity studies.

Dr Andrew Racher, Co-CEO, SynGenSys, commented: “CHO cells are the pharmaceutical industry’s gold-standard cell factories, and CHO cell-specific synthetic promoters provide an elegant solution to overcoming key productivity limitations in the industry. We are excited to release this latest update and to continue providing solutions that address evolving biomanufacturing needs.”

According to Towards Healthcare, the cell and gene therapy services market is projected to grow significantly, with estimates indicating the market size will increase from USD 11.84 billion in 2026 to approximately USD 27.16 billion by 2035, expanding at a CAGR of 9.67% from 2026 to 2035. Cell and gene therapy is a groundbreaking novel form of management that could transform healthcare forever. The uses for this type of treatment are virtually limitless for diseases that affect almost each organ system in the body. These treatments have already shown great promise in clinical trials, with some patients even experiencing complete remission from their diseases after receiving these therapies. As scientists continue on this topic, expect more breakthroughs and more guidelines to be put in place. Cell and gene therapy are two distinct healthcare treatments that intend to manage diseases in various ways. Cell therapy works by adapting or restoring particular sets of cells or using cells as carriers for therapy through the body. Gene and cell therapy have evolved as groundbreaking processes for managing diverse diseases via genetic engineering and cellular reprogramming. Cell and gene therapy solutions provide groundbreaking healthcare benefits by targeting diseases at their root genetic or cellular level rather than treating symptoms.

About SynGenSys

SynGenSys’ proprietary data and computational-driven platform allow the accurate design of synthetic gene promoters to meet strict needs and address critical bottlenecks in biomanufacturing and cell and gene therapy (CGT). The organization’s team of worldwide respected scientists has deep expertise in promoter identification and development, with a history of delivering high-impact projects for some of the biosphere’s leading biopharmaceutical and CGT organizations.

A recent report by Towards Healthcare highlights that the cell and gene therapy services market is growing, as the strength of cell and gene therapy to either prevent disease progression or offer a cure provides a significant clinical advantage over existing treatments, which are often limited to managing symptoms. Gene therapy includes the transfer of genetic material, generally in a carrier or vector, and the uptake of the gene into the right cells of the body. This includes inserting a novel copy of a gene, gene-editing technologies like CRISPR, and gene silencing. Gene and cell therapy is evolving as a groundbreaking technology for treating various diseases via genetic engineering and cellular reprogramming.